Shares climbed 2.77% to $15.95 on Wednesday, with trading volume of 22.5 million topping the 50-day average of 10.7 million.
The gain outpaced a broader market rally as the S&P 500 rose 1.46% to 7,365.12 and the Dow added 1.24% to 49,910.59.
Viatris ended the session 3.16% below its 52-week high of $16.47, reached on 26 February, extending recent momentum in a favourable market environment.
Can Viatris’s pivot to high-margin drugs escape the fierce price wars of the global generics market?
With its CFO exiting before earnings, can Viatris prove its turnaround is more than just a stock rally?